$DD

DuPont Schedules Third Quarter 2026 Earnings Conference Call

DuPont (NYSE: DD) plans to release its Q3 2026 earnings on November 3, 2026, at 6:00 a.m. ET, followed by a conference call at 8:00 a.m. ET. The event will be webcast live and a replay will be available on the company's Investor Relations webpage.

Original reporting
Published Oct 6, 2026, 11:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DD
Neutral
high confidence
Mentioned
$DD
Relevance
5/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$DDNeutralMed
01

Why it matters

The call schedule allows investors to plan positions ahead of the earnings announcement, but no new financial data is provided.

02

Market read

The announcement is a routine earnings call notice with modest trading relevance.

03

What to watch

Potential supply‑chain or regulatory developments that could affect DuPont's performance were not mentioned.

Relevance 5/10Novelty 5/10Timing: pre-market on Nov 3, 2026

Background

DuPont is a diversified chemicals and materials company that reports quarterly results. The Q3 2026 earnings release is scheduled for November 3, 2026.

Company-level read

Ticker impact

$DDNeutralHigh confidence
Context

DuPont announced the date and time of its Q3 2026 earnings release and conference call.

Expected impact

potential modest move as traders position ahead of the earnings release

Evidence & confidence

Earnings call schedules are routine but provide a clear date for market participants to align trades; no new financial metrics were disclosed.

Market effects

Provides a reference point for the chemicals and materials sector ahead of earnings season.

Limited to U.S. investors tracking DuPont and related peers.

Minor, as DuPont is a globally recognized chemical company.

Counterpoint

Some traders may ignore the call schedule, focusing on macro drivers instead of a single earnings release.

Key entities

  • DuPont

    Global chemicals and materials manufacturer (NYSE: DD).

Related articles

$DDMed

DD Downgraded by JP Morgan -- Price Target Lowered to $145

JP Morgan downgraded DuPont de Nemours (DD) to Neutral, lowering its price target from $172 to $145. GuruFocus estimates DD is 83.5% overvalued, with a GF Value of $70.97 vs. current price of $130.24. DD's P/E (TTM) is 309.35x, far above its 5-year median of 7.91x. Analysts cite concerns about growth and profitability.

$DDHigh

JPMorgan downgrades DuPont stock rating on recovery outlook

JPMorgan downgraded DuPont (NYSE:DD) to Neutral from Overweight, lowering its price target to $145 from $172. The stock trades at $132.48, considered undervalued. DuPont reported Q2 2026 earnings, beating estimates with $1.88 EPS and $1.82B revenue. BMO Capital reiterated its Outperform rating, maintaining a $186 price target.

$DDMed

Attorney General Todd Rokita leads multistate coalition to stop DuPont shell game, hold companies accountable for PFAS contamination

Attorney General Todd Rokita led a 16-state lawsuit against DuPont (EIDP), Corteva, and Vylor, alleging a transfer of assets to avoid PFAS contamination liabilities. The suit seeks to freeze assets and block dividends or buybacks. Rokita claims the companies moved valuable assets to Vylor, leaving liabilities with DuPont. The hearing is set for October 2, 2026.

$DDLow

Judge says 3M, DuPont, and Honeywell must face Connecticut firefighters' PFAS claims

A U.S. judge ruled that 3M, DuPont, Honeywell, and others must face claims from Connecticut firefighters over PFAS exposure in protective gear. The lawsuit alleges the gear, containing 3M's Scotchlite and DuPont's Kevlar, increased cancer risks. The judge allowed the case to proceed, permitting damages and medical monitoring claims. The companies argue the gear served its protective function. PFAS makers face broader scrutiny, with prior settlements totaling over $11 billion.